Amarin raised outlook on revenue, sending its shares surging +10% Tuesday.
The biopharmaceutical company lifted its 2019 revenue guidance to a range of between $380 million and $420 million, up from prior forecast of $350 million.
The company’s higher guidance comes on the back of its optimism about its Vascepa treatment for chronic cardiovascular disease. It is hopeful that Vascepa will generate “billions of dollars in revenue in the years to come”.
Amarin reported first-quarter revenue of $73.3 million, which represents a 67% jump from the same quarter of the previous year. It is also higher than the $67.3 million expected by analysts polled by FactSet.
The Aroon Indicator for AMRN entered a downward trend on May 08, 2023. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 232 similar instances where the Aroon Indicator formed such a pattern. In of the 232 cases the stock moved lower. This puts the odds of a downward move at .
The Momentum Indicator moved below the 0 level on May 26, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on AMRN as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for AMRN turned negative on May 26, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 50-day moving average for AMRN moved below the 200-day moving average on May 18, 2023. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AMRN's RSI Indicator exited the oversold zone, of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRN advanced for three days, in of 260 cases, the price rose further within the following month. The odds of a continued upward trend are .
AMRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AMRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.830) is normal, around the industry mean (6.203). AMRN has a moderately high P/E Ratio (67.114) as compared to the industry average of (30.295). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.531). AMRN's Dividend Yield (0.000) is considerably lower than the industry average of (0.027). P/S Ratio (1.331) is also within normal values, averaging (4.063).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows